Asked google what drugs Syneos has been involved with on the path to approval. Got this;


Here are some examples of drugs that Syneos Health has been involved with in some capacity:
Elevidys (Sarepta): Syneos Health provided insights on the FDA's approval of Elevidys, a gene therapy for Duchenne Muscular Dystrophy (DMD), indicating their involvement in supporting the drug's path to market.
SPRAVATO® (esketamine) CIII nasal spray (Johnson and Johnson): Approved by the FDA in August 2020 for Major Depressive Disorder, and mentioned in Syneos Health Communications' blog discussing psychedelics in mental health.
ENHERTU® (Daiichi Sankyo): Syneos Health formed a strategic coalition with Daiichi Sankyo for the development of their ADC oncology pipeline, including ENHERTU®.
Serplulimab (Fosun Pharma): Syneos Health partnered with Fosun Pharma USA to launch Serplulimab, indicating support for its market entry after regulatory approval.
Zepbound (Eli Lilly): Syneos Health Communications discussed the FDA approval of Zepbound for obesity in their blog.
Epidiolex (CBD-based prescription drug): Syneos Health Communications announced the approval of Epidiolex, the first CBD-based prescription drug for epilepsy.
l\eronlimab (CytoDyn): CytoDyn has engaged Syneos Health as a CRO for a Phase II oncology trial investigating leronlimab.
ONP-002 (Odyssey Health): Odyssey Health selected Syneos Health to support their investigational new drug application (IND) for ONP-002, a concussion drug.
Remdesivir (Veklury): Syneos Health Communications mentioned the FDA approval of Veklury (remdesivir) for the treatment of COVID-19.